Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Doctoral Network on Strains, Diagnostics and Variants

Project description

Targeting infections at the first contact

As antibiotic resistance grows, once-treatable infections are becoming deadly. Supported by the Marie Skłodowska-Curie Actions programme, the StraDiVarious project focuses on a critical early step in infection: bacterial adhesion. Surface proteins, called adhesins, allow bacteria to latch onto host cells, an essential step in disease progression. Using tools across molecular biology, infection models, and AI-driven analysis, it explores how these proteins differ between virulent and less harmful strains. By identifying strain-specific traits in key pathogens, the project will pave the way for precision diagnostics and targeted therapies. Through its international training network, StraDiVarious also prepares a new generation of researchers to combat antimicrobial resistance at its root.

Objective

Resistance to antibiotic treatment of bacterial infections is a major threat to human health worldwide, with last-resort antibiotics becoming ineffective. Bacteria like carbapenem-resistant Acinetobacter baumannii, Enterobacterales and Pseudomonas aeruginosa head the WHO global pathogen priority list. New strategies are needed to treat AMR bacteria.

Our DN StraDiVarious proposes targeting a key virulence trait: the initial interaction of bacteria with the host. Adhesion is the first and decisive step in infection, mediated by surface proteins called ‘adhesins’, which interact, either directly or indirectly, with the host cell surface to manipulate the host response. Our hypothesis is that we can distinguish between less virulent and more virulent strains of bacteria based on the fine details of their adhesins. This makes the adhesins interesting targets for both diagnostics and therapeutics.

The StraDiVarious intersectoral network (including large Pharma and SMEs) will train the next generation of researchers in this important area, focusing on the initial interaction. Our targets include the clinically most relevant pathogens from the “ESKAPE” group (eg. A. baumannii, K. pneumoniae, P. aeruginosa, E. cloacae and S. aureus). The DCs will use state-of-the-art techniques at different levels: infection (tissue/cell), biochemical interactions (cell/molecule), structure (molecule/atom) and timescale (dynamics). We will integrate this information with large clinical strain data (genomics/ proteomics) and use machine-learning to understand the cause of virulence/non-virulence at the level of individual bacterial strains and protein variants. This information will be used not only to develop next-generation strain-specific rapid diagnostics suitable for point-of-care applications but also for finding potential drug/vaccine targets. Such precision medicine will reduce load on the health-care system, avert the antibiotic crisis, and improve patient quality of life.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-DN-01

See all projects funded under this call

Coordinator

HELSINGIN YLIOPISTO
Net EU contribution
€ 629 049,60
Address
FABIANINKATU 33
00014 Helsinki
Finland
Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (10)

Partners (4)